SecBot SecBot
SECBOTREPLAY Home › Report › BBIO

BBIO · BridgeBio presented new acoramidis data at Heart Failure 2026, showing…

BridgeBio Pharma, Inc. · PRESS-RELEASE filed May 11, 2026 at 09:30 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed May 11, 2026 at 09:30 ET

BridgeBio presented new acoramidis data at Heart Failure 2026, showing a 34% reduction in cardiovascular hospitalizations versus tafamidis (indirect comparison), early separation in outpatient worsening heart failure within 30 days (HR 0.59, p<0.0001), and sTTR variability reduction associated with lower all-cause mortality (HR 0.56, p=0.014). These results strengthen acoramidis' differentiation as a near-complete TTR stabilizer and could support further market share gains in ATTR-CM.

  • Acoramidis reduced cardiovascular hospitalizations by 34% vs tafamidis (RRR 0.66, 95% CI 0.46–0.95) in a matching-adjusted indirect comparison.
  • Acoramidis reduced the risk of outpatient worsening heart failure by 41% vs placebo (HR 0.59, p<0.0001), with separation seen within 30 days and sustained through Month 30.
  • Lower sTTR variability and higher achieved sTTR levels were independently associated with reduced all-cause mortality (HR 0.56, p=0.014 and HR 0.46, p=0.014).
  • Acoramidis blunted NT-proBNP increase by ~50% across all subgroups vs placebo.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access